Arginase 1/ARG1/liver Arginase Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-59740
Key Product Details
Species Reactivity
Validated:
Human, Mouse, Rat
Cited:
Human, Mouse, Rat
Applications
Validated:
Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Peptide ELISA, Simple Western, Western Blot
Cited:
Flow Cytometry, IF/IHC, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Frozen, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence C-NHKPETDYLKPPK corresponding to C-Terminus according to NP_058830.2.
Epitope
NHKPETDYLKPPK
Reactivity Notes
Human reactivity reported in scientific literature (PMID: 28246332).
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Theoretical MW
37 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for Arginase 1/ARG1/liver Arginase Antibody
Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NB100-59740] -
Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NB100-59740] - (0.003ug/ml) staining of Mouse (A) and Rat (B) Liver lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.Applications for Arginase 1/ARG1/liver Arginase Antibody
Application
Recommended Usage
Peptide ELISA
1:64000
Simple Western
5 ug/mL
Western Blot
0.003-0.01 ug/ml
Application Notes
WB: Approx. 37 kDa band observed in mouse and rat liver lysates (calculated MW of 35 kDa band according to NP_058830.2 and 34.8kDa according to Mouse NP_031508.1). Primary incubation 1 hour at room temperature. IHC-F usage is reported in scientific literature (PMID: 24089194). Use in ICC/IF reported in scientific literature (PMID 28246332). Use in Flow Cytometry reported in (PMID: 24089194). Use in IHC reported in scientific literature (PMID: 23207546).
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Arginase 1/ARG1
Arginase and nitric oxidase synthase (NOS) compete for the same L-arginine substrate, creating a delicate balance between pathways (1). Furthermore, bioavailability of L-arginine and ARG1 expression has been implicated in several pathologies including vascular disease, neuronal disease, cardiovascular disease, immune dysfunction, inflammation, and cancer (1,3-5). For instance, ARG1 functions as a macrophage marker, defining the M2 population, while inducible nitric oxide synthase (iNOS) characterizes the M1 population; impaired M1/M2 polarization and changes in ARG1 expression is observed in diseases such as arteriogenesis, asthma, pulmonary fibrosis, and inflammatory bowel disease (1,3). In humans, arginase deficiency, known as argininemia, is an autosomal recessive metabolic disorder characterized by elevated ammonia (hyperammonemia) levels and arginine accumulation (6). Given that many arginase-associated diseases are characterized by upregulation in expression of ARG1, ARG2, or both, arginase inhibitors are currently being studied as a potential therapeutic approach (1,4).
References
1. S Clemente, G., van Waarde, A., F Antunes, I., Domling, A., & H Elsinga, P. (2020). Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21155291
2. Uniprot (P05089)
3. Kieler, M., Hofmann, M., & Schabbauer, G. (2021). More than just protein building blocks: How amino acids and related metabolic pathways fuel macrophage polarization. The FEBS Journal. Advance online publication. https://doi.org/10.1111/febs.15715
4. Shosha, E., Fouda, A. Y., Narayanan, S. P., Caldwell, R. W., & Caldwell, R. B. (2020). Is the Arginase Pathway a Novel Therapeutic Avenue for Diabetic Retinopathy?. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9020425
5. Correale J. (2021). Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.600428
6. Morales, J. A., & Sticco, K. L. (2020). Arginase Deficiency. In StatPearls. StatPearls Publishing.
Long Name
Liver-Type Arginase
Alternate Names
AI, ARG1, Arginase-1, Liver Arginase, PGIF, Type I Arginase
Gene Symbol
ARG1
UniProt
Additional Arginase 1/ARG1 Products
Product Documents for Arginase 1/ARG1/liver Arginase Antibody
Product Specific Notices for Arginase 1/ARG1/liver Arginase Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...